Protein Stability Testing Services: Comprehensive Biophysical Characterisation for Biologics Development

As an independent third-party analytical service provider, we offer comprehensive protein stability testing for therapeutic antibodies, recombinant proteins, vaccines, biosimilars, enzymes, and fusion proteins. Protein stability – the ability of a protein to maintain its native structure, conformation, and biological activity over time – is a critical quality attribute (CQA) for biopharmaceutical development, formulation design, manufacturing process validation, and regulatory submissions. Instability can lead to aggregation, fragmentation, deamidation, oxidation, misfolding, and loss of potency, which not only compromise product safety and efficacy but also increase manufacturing costs and regulatory risk. Our accredited laboratory follows ICH Q5C (stability testing of biotechnological/biological products) and ICH Q6B (specifications) guidelines, employing a suite of orthogonal biophysical, biochemical, and separation techniques: differential scanning calorimetry (DSC), differential scanning fluorimetry (DSF), circular dichroism (CD) spectroscopy, size‑exclusion chromatography (SEC), dynamic light scattering (DLS), intrinsic fluorescence, and accelerated stability studies. This article outlines our protein stability testing capabilities – including scope, key test items, and standard test methods – to help biopharmaceutical companies, CROs, and academic researchers evaluate and predict the conformational, colloidal, and long‑term stability of protein therapeutics.

1. Our Testing Scope for Protein Molecular Stability

We cover a wide range of protein types, stability domains, and experimental conditions:

By protein type / molecule class: Monoclonal antibodies (IgG1, IgG2, IgG4, bispecific, Fc‑fusion); Recombinant cytokines, growth factors, and hormones (e.g., insulin, EPO, G‑CSF); Enzymes (proteases, kinases, polymerases, metabolic enzymes); Vaccine antigens (viral proteins, subunit vaccines, virus‑like particles – VLPs); Fusion proteins and scaffold proteins; Biosimilar and innovator comparability panels.

By stability dimension: Conformational (structural) stability – resistance to unfolding (thermal, chemical, mechanical); Colloidal stability – resistance to aggregation, precipitation, and opalescence; Long‑term storage stability (real‑time and accelerated ageing) – maintenance of native structure and function over shelf life; Forced degradation stability – response to stress conditions (heat, light, oxidation, freeze‑thaw, agitation); Formulation compatibility – effect of excipients (sugars, surfactants, salts, preservatives) on stability.

By biophysical technique: Differential scanning calorimetry (DSC) – thermal unfolding temperature (T_m), calorimetric enthalpy (ΔH), cooperativity; Differential scanning fluorimetry (DSF) – T_m using fluorescent dyes (SYPRO Orange) or intrinsic tryptophan fluorescence; Circular dichroism (CD) – secondary structure (far‑UV CD) and tertiary structure (near‑UV CD); Intrinsic fluorescence – tertiary structure and conformational changes (tryptophan/tyrosine emission); Size‑exclusion chromatography (SEC) – aggregation (high molecular weight species), fragmentation (low molecular weight species); Dynamic light scattering (DLS) – hydrodynamic radius (R_h), polydispersity index (PdI), aggregation tendency; Static light scattering (SLS) – molecular weight and aggregation; Nanoparticle tracking analysis (NTA) – sub‑visible particle count; Accelerated stability (real‑time / forced degradation) – purity, potency, and aggregation over time.

By stress / condition: Thermal stress (elevated temperatures: 25°C, 37°C, 40°C, 50°C, 60°C); Mechanical stress (agitation, shaking, stirring, pumping); Freeze‑thaw stress (multiple cycles, controlled freeze/thaw rates); Chemical stress (oxidation – H₂O₂, light – UV/visible, pH extremes, metal ions); Osmotic stress (high salt or cryoprotectant concentrations).

By industry / regulatory application: Pre‑formulation screening – ranking of candidates and excipients; Formulation development – optimisation of pH, buffer, tonicity modifiers, surfactants; Process development – impact of purification, concentration, fill‑finish on stability; Comparability studies – pre‑ and post‑manufacturing change (process, site, scale); Biosimilar analytical similarity – establishing similarity in stability profiles; Lot release and stability indicating assays; IND/BLA submission – characterisation of degradation pathways and setting shelf‑life.

2. Key Test Items & Measurements We Perform

Our protein stability testing services are organised into four integrated domains, covering conformational stability, colloidal stability, forced degradation, and long‑term storage.

2.1 Conformational Stability – Thermal & Chemical Unfolding

These assays measure the energy required to unfold the protein and its resistance to thermal or chemical denaturation.

Melting temperature (T_m) by DSC – The gold standard for thermal stability. The protein solution (and reference buffer) is heated at a controlled rate (typically 1‑2°C/min) while the heat capacity is measured. The T_m (midpoint of unfolding) and the calorimetric enthalpy (ΔH) are derived. For multi‑domain proteins (e.g., antibodies), up to three T_m values (CH2, CH3, Fab) may be observed. Results are reported as T_m1, T_m2, T_m3 (°C) and ΔH (kJ/mol). Lower T_m values indicate greater susceptibility to unfolding.

T_m by DSF (SYPRO Orange) – A higher‑throughput, lower‑sample alternative to DSC. The protein is mixed with the environmentally sensitive dye SYPRO Orange, which fluoresces when bound to hydrophobic patches exposed during unfolding. As temperature ramps (25‑95°C, 2‑4°C/min), the fluorescence increase is monitored; the inflection point (maximum of the first derivative) gives T_m. Requires only 5‑10 μg of protein per well, suitable for screening many formulation conditions. We report T_m (°C) and the shape of the unfolding transition (cooperativity).

Chemical unfolding (urea or guanidine hydrochloride) – The protein is incubated with increasing concentrations of denaturant, and the change in intrinsic tryptophan fluorescence (or CD signal) is measured. The mid‑point of denaturation (C_m) is reported. This test is particularly useful when thermal unfolding is irreversible or when comparing the stability of mutants under similar solution conditions.

2.2 Colloidal Stability – Aggregation & Particle Characterisation

These assays measure the tendency of the protein to self‑associate or form visible/invisible particles.

Size‑exclusion chromatography (SEC) – The primary method for quantifying soluble aggregates (high molecular weight species – HMWS) and fragments (low molecular weight species – LMWS). Samples are separated on a calibrated column (e.g., TSKgel G3000SWXL, Waters BEH200) with UV detection (280 nm). We report % HMWS (dimer and higher order), % monomer, and % LMWS. LOD for HMWS is typically 0.05‑0.1%. SEC is also used to monitor real‑time stability (0, 2, 4 weeks, etc.) under accelerated and storage conditions.

Dynamic light scattering (DLS) – Measures the hydrodynamic radius (R_h) and polydispersity index (PdI) of the protein. It detects large aggregates (>5‑10 nm) and can monitor aggregation kinetics at different temperatures. Results are reported as Z‑average diameter (nm) and PdI. For a stable monoclonal antibody, R_h is typically 5‑7 nm with PdI < 0.15. An increase in R_h or PdI over time indicates aggregation.

Static light scattering (SLS) – Coupled with SEC (SEC‑MALS) to determine absolute molecular weight of the monomer and aggregates, and to distinguish between reversible and irreversible association.

Sub‑visible particle counting (HIAC / MFI) – Quantifies particles ≥ 2 μm, ≥ 10 μm, and ≥ 25 μm per USP <787> (proteinaceous) and USP <788>. Elevated particle counts (e.g., > 6,000 per container for ≥ 10 μm) suggest instability or particulate contamination.

Turbidity / opalescence – Measured by absorbance at 350 nm (or 405 nm) using a spectrophotometer. Increased turbidity indicates protein aggregation or phase separation.

2.3 Secondary & Tertiary Structural Integrity (CD & Fluorescence)

These techniques assess whether the protein retains its native secondary and tertiary structure after thermal, chemical, or aging stress.

Far‑UV circular dichroism (CD) – Measures the secondary structure (α‑helix, β‑sheet, random coil). Wavelength range 190‑260 nm. A decrease in mean residue ellipticity (θ) at 218 nm (β‑sheet) or 222 nm (α‑helix) indicates unfolding. We report full spectra and percent secondary structure composition via deconvolution algorithms (CDPro, BeStSel).

Near‑UV CD – Monitors tertiary structure (aromatic residues – Tyr, Trp, Phe). Wavelength range 250‑350 nm. Changes in near‑UV CD signal indicate conformational changes in the protein core. Reported as difference spectra (stress vs. control).

Intrinsic tryptophan fluorescence – Tryptophan emission maximum (λ_max) shifts from ~330 nm (buried, hydrophobic environment) to ~350 nm (exposed, aqueous) upon unfolding. We measure fluorescence spectra (excitation 280 nm or 295 nm) and report λ_max and fluorescence intensity at 330 nm and 350 nm. A red shift indicates tertiary structural change.

2.4 Long‑Term & Accelerated Stability Studies (ICH Q5C)

We design and execute stability studies according to ICH Q5C guidelines for biotechnological/biological products.

Real‑time stability – Storage at recommended conditions (e.g., 2‑8°C for liquid formulations, -20°C or -70°C for frozen) for up to 24‑36 months. Sampling time points: 0, 3, 6, 9, 12, 18, 24 months. Test parameters: SEC (aggregation/fragmentation), activity/potency (cell‑based or binding assay), pH, appearance (colour, clarity), sub‑visible particles, and optionally DSF/CD if stability‑indicating signal is required. The shelf‑life is estimated using statistical analysis (e.g., linear regression with 95% confidence bounds).

Accelerated stability – Storage at elevated temperatures (25°C, 37°C, 40°C) for 1‑6 months to accelerate degradation processes (oxidation, deamidation, aggregation, fragmentation). Arrhenius extrapolation can predict degradation rates at storage temperature, helping set shelf‑life and identify critical degradation pathways.

Forced degradation studies – Protein is exposed to stress conditions to identify potential degradation products and to validate stability‑indicating assays. Typical stresses include: thermal (40‑70°C, 1‑7 days); oxidation (0.01‑0.1% H₂O₂, 2‑24 hours); light exposure (1.2 million lux·h visible + 200 W·h/m² UV); freeze‑thaw (3‑10 cycles, ‑80°C to room temperature); agitation (shaking at 200‑300 rpm for 48‑72 hours). Samples are analysed by SEC, CE‑SDS, fluorescence, and activity to determine degradation extent and pathways.

3. Standard Test Methods We Apply

All tests are performed according to ICH guidelines, pharmacopoeial methods (USP, Ph. Eur.), and internally validated protocols. Our laboratory is ISO/IEC 17025 accredited for many of these biophysical and separation methods and follows GMP principles for stability studies.

3.1 Conformational Stability Standards

Differential scanning calorimetry (DSC): no single pharmacopoeial chapter, but we follow industry best practices (e.g., using a MicroCal PEAQ‑DSC or VP‑DSC) with heating rate 1‑2°C/min, 10‑30 °C above the expected T_m, and buffer‑buffer reference subtraction. Data analysis is performed using MicroCal Origin software (non‑two‑state model for multi‑domain proteins).

Differential scanning fluorimetry (DSF): We follow the protocol described by Niesen et al. (2007) and adapted for high‑throughput screening. SYPRO Orange dye is used at 5× concentration; protein at 0.2‑1 mg/mL; assay volume 20‑50 μL in a 96‑well plate; temperature ramp 25‑95°C at 2 °C/min. Data collected on a real‑time PCR instrument (e.g., Bio‑Rad CFX96). T_m is calculated as the maximum of the first derivative (dd fluorescence / dT).

Circular dichroism (CD): We use a Jasco J‑1500 or Chirascan spectrometer. Far‑UV CD: 0.1‑0.5 mg/mL protein, 0.1 mm pathlength cuvette, wavelength 190‑260 nm, bandwidth 1 nm, scanning speed 20‑50 nm/min. Near‑UV CD: 1‑2 mg/mL, 10 mm pathlength, 250‑350 nm. Raw data are converted to mean residue ellipticity (deg·cm²·dmol⁻¹) and secondary structure content is estimated using CDPro or BeStSel.

3.2 Colloidal Stability & Aggregation Standards

Size‑exclusion chromatography (SEC): Per USP <621> and Ph. Eur. 2.2.30. Columns: TSKgel G3000SWXL (7.8 mm × 300 mm) or Waters BEH200 (4.6 mm × 150 mm). Mobile phase: 0.2 M phosphate buffer + 0.05% sodium azide (or 0.2 M arginine) pH 6.8. Flow rate: 0.5‑1.0 mL/min; injection volume 10‑50 μg protein; detection at 280 nm. Data are integrated to calculate % monomer, % HMWS, and % LMWS. System suitability is verified using a reference standard (e.g., BSA or pooled human IgG).

Dynamic light scattering (DLS): Performed on a Malvern Zetasizer Nano ZS or Wyatt DynaPro Plate Reader. Backscatter angle 173°, measurement temperature 25°C, viscosity and refractive index corrected for the buffer. Sample concentration 0.5‑10 mg/mL. At least 10 measurements per sample. We report Z‑average diameter (nm), polydispersity index (PdI), and count rate (kcps).

Sub‑visible particle counting: Light obscuration (HIAC) per USP <788>; micro‑flow imaging (MFI) per USP <787> (for proteinaceous particles). Sample volume 1‑5 mL (depending on container size). Results are reported as particles/mL for size thresholds ≥ 2 μm, ≥ 10 μm, and ≥ 25 μm.

3.3 Forced Degradation & Stability Study Standards

ICH Q5C (Stability testing of biotechnological/biological products). – Defines storage conditions, sampling frequency, testing attributes, and data presentation. We follow this guideline for all stability studies submitted to regulatory agencies.

ICH Q6B (Specifications for biotechnological/biological products). – Provides guidance on setting acceptance criteria for purity, potency, and other attributes, including stability‑indicating assays.

ICH Q1A (Stability testing of new drug substances and products) – Applicable to small molecules, but the bracketing and matrixing principles are often applied to biologics.

USP <1057> (Biotechnology‑derived articles – protein stability). – Provides an overview of biophysical methods (DSC, CD, DLS, fluorescence) as stability‑indicating assays.

4. Why Choose Our Third‑Party Protein Stability Testing Services?

As an independent laboratory, we provide unbiased, accurate, and regulatorily compliant data. Our strengths include:

ISO/IEC 17025 accreditation – Our core biophysical and chromatography methods are CNAS/CMA accredited, with regular participation in proficiency testing (e.g., NIST mAb reference material studies, SEC round robins).

Multi‑instrument, orthogonal platform – We operate DSC (MicroCal VP‑Capillary), DSF (Bio‑Rad CFX96), CD (Jasco J‑1500), fluorescence spectrometer (Horiba FluoroMax), SEC‑HPLC (Agilent 1260 Infinity II), DLS (Malvern Zetasizer), and particle counters (HIAC, MFI). This allows us to cross‑validate stability results and identify discrepancies.

End‑to‑end stability programme management – We can design the stability protocol, prepare samples (including stress studies), perform all time‑point tests, manage the stability chamber (2‑8°C, 25°C/60% RH, 40°C/75% RH), analyse data, and produce an ICH‑compliant final report.

Low sample consumption – DSF requires as little as 5 μg protein per condition; CD and fluorescence use 50‑200 μg; SEC uses 50‑100 μg; DLS uses 10‑20 μL of sample (backflushed).

Fast turnaround – A full stability‑indicating characterisation (DSC, DSF, CD, SEC, DLS) for a single formulation can be completed within 1‑2 weeks. Forced degradation studies (5 conditions, 3 time points) typically require 2‑3 weeks. Long‑term stability monitoring is scheduled over months or years as per customer needs.

Detailed reporting – Reports include original DSC thermograms (heat capacity vs. temperature), DSF melt curves, CD spectra, SEC chromatograms, DLS correlation functions, stability data tables (time vs. % monomer, etc.), statistical analysis (shelf‑life estimation), and clear conclusions regarding conformational and colloidal stability.

Confidentiality – Full protection of your protein sequences, constructs, formulation compositions, and proprietary data.

Consultative support – Our biophysicists and formulation scientists assist with: selection of the most informative stability assays for your molecule; interpretation of multi‑domain melting profiles (e.g., antibodies); correlation of biophysical data with biological activity; root‑cause analysis of aggregation (e.g., hydrophobic vs. electrostatic); optimisation of formulation buffers and excipients.

Whether you need to screen excipients for a monoclonal antibody formulation, compare the stability of a biosimilar to its reference product, characterise the thermal unfolding of an enzyme for process development, or generate ICH‑compliant stability data for a regulatory filing, our protein stability testing experts are ready to deliver reliable, actionable results.

Get Started with Your Protein Stability Testing Project

Contact our team with your protein type, concentration, available quantity, required assays (e.g., DSC, SEC, DSF, forced degradation), and any specific formulation or stress conditions. We will provide a detailed quotation, sample submission guidelines (volume, buffer composition, recommended storage), and a testing schedule. Let us help you ensure that your protein therapeutic remains safe, effective, and stable throughout its shelf life.

This article provides an overview of our protein molecular stability testing capabilities. For specific test methods, sample quantity, and pricing, please request a tailored service proposal.